帕罗西汀缓解脑卒中后焦虑抑郁的临床观察

The study on the clinical efficacy of Paroxetine on treatment in patients with anxiety and depression after stroke

目的观察帕罗西汀治疗脑卒中后焦虑抑郁的临床疗效。方法选取确诊为脑卒中后抑郁焦虑患者70例,随机平均分成对照组和研究组。对照组给予脑血管病常规治疗和心理治疗,研究组在对照组治疗的基础上加服帕罗西汀治疗,疗程为30 d。两组患者均在治疗前后进行汉密尔顿抑郁量表(HAMD)和焦虑量表(HAMA)评分,并根据得分减少率判定临床疗效。结果 (1)对照组治疗后HAMD评分(8.85±2.16)与治疗前(11.98±2.61)相比,差异无统计学意义(P>0.05),HAMD评分差值为(3.24±1.78);研究组HAMD评分(6.29±2.35)与治疗前(11.39±2.27)相比,差异有统计学意义(P<0.05),HAMD评分差值为(5.23±1.96)。两组HAMD差值相比,差异有统计学意义(P<0.05)。(2)对照组治疗后HAMA评分(7.55±1.36)与治疗前(9.52±1.64)相比,差异无统计学意义(P>0.05),HAMA评分差值为(2.05±1.78);而研究组HAMA评分(4.29±1.05)与治疗前(9.63±1.28)相比,差异有统计学意义(P<0.05),HAMA评分差值为(5.44±1.13)。两组HAMA差值相比,差异有统计学意义(P<0.05)。(3)与对照组治疗总有效率28.6%相比,研究组的总有效率提高到91.4%,差异有显著统计学意义(P<0.01)。结论帕罗西汀治疗脑卒中后焦虑抑郁临床疗效明显,值得推广。

Objective To observe the clinical efficacy of paroxetine on treatment in patients with anxiety and depression after stroke. Methods 70 patients who were diagnosed as anxiety and depression after stroke were taken. They were randomly, equally divided into control group and treatment group. The control group was given conventional therapy for cerebral vascular disease and psychological treatment. The treatment group was given the same treatment. Besides that, paroxetine was taken. The treatment was for 30 days. The patients of two groups were scored according to Hamilton Depression Scale （HAMD） and self-rating anxiety scale （HAMA） at the time ofpre-treatment and post-treatment. The clinical efficacy was judged by the score reduction rate. Results （1） The per-treatment HAMD score v.s. post-treatment is （8.85 ±2.16） v.s. （11.98 ±2.61） in the control group. There is no significant difference （P〉0.05）, HAMD score difference was （3.24± 1.78）; and the per-treatment HAMD score v.s. post-treatment is （6.29 ± 2.35） v.s. （11.39 ± 2.27） in treatment group, there were significant differences （P〈0.05）, HAMD score difference was （5.23 ±1.96）. Compared two groups of HAMD difference, there is a statistically significant difference （P〈0.05）. （2） The per-treatment HAMA score v.s. post-treatment is （7.55 ± 1.36） v.s. （9.52 ± 1.64） in the control group. There is no significant difference （P〉0.05）, HAMA score difference was （2.05 ± 1.78）; and the per-treatment HAMA score v.s. post-treatment is （4.29 ±1.05） V.S. （9.63 ± 1.28） in treatment group, there were significant differences （P〈0.05）, HAMA score difference was （5.44 ± 1.13）. Compared two groups of HAMA difference, there is a statistically significant difference （P〈0.05）. （3） The total effective rate of control group was 28.6%, and the total effective rate of treatment group was increased to 91.4%, there were significant differences （P〈0.01）. Conclusion Paroxetine had clinical curative effect in the treatment of anxiety and depression after stroke, and it was worthy of promotion.